Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that sales of Crohn's disease (CD) drug therapies will increase from $713 million in 2002 to nearly $1.2 billion in 2012. According to a new Pharmacor study entitled Crohn's Disease, this sales growth will arise primarily from the continued uptake of Centocor/Schering- Plough/Tanabe Seiyaku's Remicade (the only biological agent currently approved for CD) and the launch of other emerging biological agents.

"Many of these new biological agents will be priced significantly higher than conventional CD therapies such as immunosuppressants, corticosteroids, and aminosalicylates. Thus, even minimal increases in patient share for these agents will result in substantial growth in CD sales," said Melissa Garland, analyst at Decision Resources.

About Crohn's Disease

CD is a chronic, relapsing/remitting inflammatory disease that predominately affects the small intestine, the large intestine, and the rectum. In 2002, approximately 500,000 people in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) were diagnosed with CD.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Crohn's Disease is an Immune and Inflammatory Disorders study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Drug Market For Multiple Sclerosis Will Be Driven By [Growth In] The Number Of Drug-Treated Patients

View Now